Shots:
- Suzhou Siran Biotechnology has granted GSK a global exclusive license to SA030, a long-acting, siRNA oligonucleotide, for the treatment of metabolic & vascular disease (excl. mainland China, Hong Kong, Macau & Taiwan)
- As per the deal, Siran Bio will receive an upfront fee & potential development, regulatory & commercial milestones payments up to $1.005B, plus tiered royalties on global product net sales (excl. Greater China)
- SiranBio will lead clinical development of SA030 through P-I completion, after which GSK will assume responsibility for development, regulatory filings, & commercialization in the licensed territories
Ref: Siran Bio | Image: GSK & Siran Bio | Press Release
Related News: The US FDA Grants Priority Review and Breakthrough Therapy Designation to GSK’s Bepirovirsen for Chronic Hepatitis B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
